Header Logo

Connection

Christopher Goetz to Middle Aged

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Middle Aged.
Christopher Goetz
Connection Strength
1.540
Middle Aged
  1. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.076
  2. Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS). Mov Disord. 2017 Aug; 32(8):1244-1249.
    View in: PubMed
    Score: 0.055
  3. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
    View in: PubMed
    Score: 0.053
  4. Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
    View in: PubMed
    Score: 0.047
  5. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9.
    View in: PubMed
    Score: 0.045
  6. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord. 2014 Sep; 29(10):1252-7.
    View in: PubMed
    Score: 0.044
  7. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
    View in: PubMed
    Score: 0.041
  8. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
    View in: PubMed
    Score: 0.039
  9. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug; 27(9):1129-36.
    View in: PubMed
    Score: 0.039
  10. Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Parkinsons Dis. 2012; 2(1):23-7.
    View in: PubMed
    Score: 0.038
  11. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord. 2012 Feb; 27(2):248-53.
    View in: PubMed
    Score: 0.038
  12. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
    View in: PubMed
    Score: 0.037
  13. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
    View in: PubMed
    Score: 0.036
  14. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
    View in: PubMed
    Score: 0.035
  15. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
    View in: PubMed
    Score: 0.034
  16. Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord. 2009 Mar 15; 24(4):551-6.
    View in: PubMed
    Score: 0.031
  17. Comparison of tic characteristics between children and adults. Mov Disord. 2008 Dec 15; 23(16):2407-11.
    View in: PubMed
    Score: 0.031
  18. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008 Dec 15; 23(16):2398-403.
    View in: PubMed
    Score: 0.031
  19. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.030
  20. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.030
  21. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.029
  22. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
    View in: PubMed
    Score: 0.027
  23. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.025
  24. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.025
  25. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.023
  26. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.021
  27. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1146-9.
    View in: PubMed
    Score: 0.021
  28. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord. 2003 Jul; 18(7):831-2.
    View in: PubMed
    Score: 0.021
  29. Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol. 2003 May; 53(5):616-23.
    View in: PubMed
    Score: 0.021
  30. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.021
  31. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003 Mar 25; 60(6):917-22.
    View in: PubMed
    Score: 0.021
  32. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.020
  33. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.019
  34. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
    View in: PubMed
    Score: 0.018
  35. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel? J Parkinsons Dis. 2021; 11(1):3-8.
    View in: PubMed
    Score: 0.018
  36. Efficacy, tolerability, and safety of an innovative medical device for improving oral accessibility during oral examination in special-needs patients: A multicentric clinical trial. PLoS One. 2020; 15(9):e0239898.
    View in: PubMed
    Score: 0.017
  37. Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. Neuroepidemiology. 2020; 54(4):356-362.
    View in: PubMed
    Score: 0.017
  38. Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
    View in: PubMed
    Score: 0.016
  39. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 10; 33(10):1601-1608.
    View in: PubMed
    Score: 0.015
  40. Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord. 2018 10; 33(10):1643-1646.
    View in: PubMed
    Score: 0.015
  41. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018 07; 52:83-89.
    View in: PubMed
    Score: 0.015
  42. Validation study of the hoehn and yahr scale included in the MDS-UPDRS. Mov Disord. 2018 04; 33(4):651-652.
    View in: PubMed
    Score: 0.014
  43. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
    View in: PubMed
    Score: 0.014
  44. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.013
  45. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
    View in: PubMed
    Score: 0.013
  46. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.013
  47. The Mini-OAKHQOL for knee and hip osteoarthritis quality of life was obtained following recent shortening guidelines. J Clin Epidemiol. 2016 Jan; 69:70-8.
    View in: PubMed
    Score: 0.012
  48. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.012
  49. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6.
    View in: PubMed
    Score: 0.012
  50. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
    View in: PubMed
    Score: 0.011
  51. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9.
    View in: PubMed
    Score: 0.011
  52. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
    View in: PubMed
    Score: 0.011
  53. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
    View in: PubMed
    Score: 0.010
  54. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord. 2013 Sep; 19(9):806-11.
    View in: PubMed
    Score: 0.010
  55. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.010
  56. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403.
    View in: PubMed
    Score: 0.010
  57. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord. 2012 May; 27(6):727-34.
    View in: PubMed
    Score: 0.010
  58. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.009
  59. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012 Jan; 27(1):79-83.
    View in: PubMed
    Score: 0.009
  60. Association between antipsychotics and body mass index when treating patients with tics. J Child Adolesc Psychopharmacol. 2010 Aug; 20(4):277-81.
    View in: PubMed
    Score: 0.009
  61. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
    View in: PubMed
    Score: 0.008
  62. Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet. 2010 Jan 15; 19(2):299-312.
    View in: PubMed
    Score: 0.008
  63. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.008
  64. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
    View in: PubMed
    Score: 0.007
  65. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007 Feb; 64(2):261-5.
    View in: PubMed
    Score: 0.007
  66. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2078-81.
    View in: PubMed
    Score: 0.007
  67. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
    View in: PubMed
    Score: 0.006
  68. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.006
  69. Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
    View in: PubMed
    Score: 0.006
  70. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.006
  71. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.005
  72. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.005
  73. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.005
  74. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003 May; 53(5):624-9.
    View in: PubMed
    Score: 0.005
  75. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.